[Research update of ocriplasmin for symptomatic vitreomacular adhesion].

Ocriplasmin is a recombinant truncated form of human serine protease plasmin with proteolytic activity to induce vitreous liquefaction and weaken vitreomacular adhesion, thereby facilitating posterior vitreous detachment and acting as a potential alternative to replace the more traumatic vitrectomy which can result in incomplete vitreoretinal separation. Intravitreal ocriplasmin for symptomatic vitreomacular adhesion has been systematically evaluated in clinical trials. Ocriplasmin at the recommended dose of a single 125 µg intravitreal injection has recently been approved for the treatment of symptomatic VMA in the USA and EU. This review is aiming to highlight the research update of ocriplasmin.